Advertisement

Letter re: Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: An observational study

Published:November 17, 2022DOI:https://doi.org/10.1016/j.ejca.2022.10.010
      With great interest, we read the article entitled “Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: An observational study” written by Basak EA et al. [
      • Basak E.A.
      • Vermeer N.S.
      • de Joode K.
      • Hurkmans D.P.
      • Velthuis D.E.
      • Hoop E.O.
      • et al.
      Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: an observational study.
      ].
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Basak E.A.
        • Vermeer N.S.
        • de Joode K.
        • Hurkmans D.P.
        • Velthuis D.E.
        • Hoop E.O.
        • et al.
        Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: an observational study.
        Eur J Cancer. 2022 Oct; 174: 113-120
        • Kichenadasse G.
        • Miners J.O.
        • Mangoni A.A.
        • Rowland A.
        • Hopkins A.M.
        • Sorich M.J.
        Association between body mass index and overall survival with immune checkpoint inhibitor therapy for advanced non-small cell lung cancer.
        JAMA Oncol. 2020 Apr 1; 6: 512-518
        • Cortellini A.
        • Bersanelli M.
        • Santini D.
        • Buti S.
        • Tiseo M.
        • Cannita K.
        • et al.
        Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: a multicentre analysis of immune-related adverse events.
        Eur J Cancer. 2020 Mar; 128: 17-26
        • Pavan A.
        • Calvetti L.
        • Dal Maso A.
        • Attili I.
        • Del Bianco P.
        • Pasello G.
        • et al.
        Peripheral blood markers identify risk of immune-related toxicity in advanced non-small cell lung cancer treated with immune-checkpoint inhibitors.
        Oncol. 2019 Aug; 24: 1128-1136
        • Guzman-Prado Y.
        • Ben Shimol J.
        • Samson O.
        Body mass index and immune-related adverse events in patients on immune checkpoint inhibitor therapies: a systematic review and meta-analysis.
        Cancer Immunol Immunother. 2021 Jan; 70: 89-100
        • Lee P.Y.
        • Oen K.Q.X.
        • Lim G.R.S.
        • Hartono J.L.
        • Muthiah M.
        • Huang D.Q.
        • et al.
        Neutrophil-to-Lymphocyte ratio predicts development of immune-related adverse events and outcomes from immune checkpoint blockade: a case-control study.
        Cancers (Basel). 2021 Mar; 13: 1308
        • Austin P.C.
        • Lee D.S.
        • Fine J.P.
        Introduction to the analysis of survival data in the presence of competing risks.
        Circulation. 2016 Feb 9; 133: 601-609
        • Nolan E.K.
        • Chen H.Y.
        A comparison of the Cox model to the Fine-Gray model for survival analyses of re-fracture rates.
        Arch Osteoporos. 2020 Jun 9; 15: 86

      Linked Article